MIF- Thyroxine Interactions in the Pathogenesis of Pulmonary Arterial Hypertension

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02858791

Enrollment

Registered

2016-08-08

Start date

2013-02-28

Completion date

2017-12-21

Last updated

2018-01-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Interstitial Lung Disease, Pulmonary Arterial Hypertension, Pulmonary Hypertension

Brief summary

The investigators will investigate the interrelationship of macrophage migration inhibitory factor (MIF) and free T4 in patients with PAH.

Detailed description

The investigators will test our hypothesis and accomplish our objectives by pursuing three Specific Aims: To investigate the interrelationship between macrophage migration inhibitory factor (MIF) and free T4 in patients with PAH with a working hypothesis that an increased release of MIF into the pulmonary vasculature during cardiopulmonary exercise changes the normal balance between plasma MIF and T4.

Interventions

None listed

Study design

Observational model

CASE_CONTROL

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

* Subject must be at least 18 years of age and have confirmed pulmonary hypertension (PH) and interstitial lung disease (ILD). * ILD was identified on high resolution computed tomography along with a total lung capacity (TLC) \<70% of predicted value on pulmonary function tests (PFTs) with no evidence of pulmonary hypertension on echocardiogram. * PAH group patients were defined as patients with a mean pulmonary artery pressure \>25 mmHg at rest and a wedge pressure of \<15 mmHg (millimeters of mercury), measured by right heart catheterization (WHO group I PAH). * PH+ILD group, subjects with evidence of ILD on high resolution CT Scan and mean pulmonary artery pressure \>25 mmHg on right heart catheterization. * Patient with evidence of Chronic thromboembolic disease on CT angiogram and mean pulmonary artery pressure \>25mmHg on right heart catheterization. (WHO group IV) * Patient with Pulmonary Hypertension due to other conditions, such as Sarcoidosis, Gauchers disease, Hemolytic Anemia and Myeloproliferative disorders. * Normal control group: Subjects without cardiopulmonary disease, with a normal PFT and ECG.

Exclusion criteria

* Failure to obtain informed consent; * Pregnancy * Subjects with cardiopulmonary disease other than PH and ILD; * Unexplained abnormal PFT, ECG, Routine blood/chemistries test * History or existing other sever organ/system diseases * Defined Acute pulmonary embolism * Age \< 18 years

Design outcomes

Primary

Measure	Time frame	Description
To examine the MIF-T4 relationship in patients before/after a standardized exercise challenge	up to 30 mins	Assess levels of the proinflammatory cytokine macrophage migration inhibitory factor (MIF) before/after standard exercise challenge

Countries

United States

Outcome results